OncoSil Medical (ASX:OSL), a pancreatic cancer device company, has rallied on clinical and regulatory progress. In July 2026, Pengana Capital Group reported OncoSil rose 64% after presenting results from its TRIPP-FXX study at the European Society for Medical Oncology congress. In June, Pengana noted a 39% rise after OncoSil received approval from Australia's Therapeutic Goods Administration. OncoSil Medical operates in the Healthcare sector within the Life Sciences Tools and Services industry, and Thesis Tracker has captured 5 comments from 1 fund manager, Pengana Capital Group. Founded in 2005 and headquartered in Macquarie Park, Sydney, OncoSil develops and commercialises the OncoSil device, a localised radiation therapy that implants phosphorus-32 microparticles directly into pancreatic tumours alongside chemotherapy, with approvals in Europe and other markets and a pathway toward the United States, targeting one of the hardest-to-treat cancers.